Literature DB >> 8165600

Requirement for both D domains of the propolypeptide in von Willebrand factor multimerization and storage.

A M Journet1, S Saffaripour, D D Wagner.   

Abstract

Biosynthesis of the adhesive glycoprotein von Willebrand factor (vWf) by endothelial cells results in constitutive secretion of small multimers and storage of the largest multimers in rod-shaped granules called Weibel-Palade bodies. This pattern is reproduced by expression of pro-vWf in heterologous cells with a regulated pathway of secretion, that store the recombinant protein in similar elongated granules. In these cells, deletion of the vWf prosequence prevents vWf storage. The prosequence, composed of two homologous domains (D1 and D2), actively participates in vWf multimer formation as well. We expressed deletion mutants lacking either the D1 domain (D2vWf) or the D2 domain (D1vWf) in various cell lines to analyze the relative importance of each domain in vWf multimerization and storage. Both proteins were secreted efficiently without being retained in the endoplasmic reticulum. Despite this, neither multimerized past the dimer stage and they were not stored. We conclude that several segments of the prosequence are jointly involved in vWf multimerization and storage.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8165600

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  12 in total

1.  The mutation N528S in the von Willebrand factor (VWF) propeptide causes defective multimerization and storage of VWF.

Authors:  Sandra L Haberichter; Ulrich Budde; Tobias Obser; Sonja Schneppenheim; Cornelia Wermes; Reinhard Schneppenheim
Journal:  Blood       Date:  2010-03-24       Impact factor: 22.113

2.  Sequence and structure relationships within von Willebrand factor.

Authors:  Yan-Feng Zhou; Edward T Eng; Jieqing Zhu; Chafen Lu; Thomas Walz; Timothy A Springer
Journal:  Blood       Date:  2012-04-06       Impact factor: 22.113

3.  Effects of the mutant von Willebrand factor gene in von Willebrand disease.

Authors:  Z Zhang; M Lindstedt; M Blombäck; M Anvret
Journal:  Hum Genet       Date:  1995-10       Impact factor: 4.132

4.  A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis.

Authors:  C Denis; N Methia; P S Frenette; H Rayburn; M Ullman-Culleré; R O Hynes; D D Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

5.  von Willebrand factor propeptide: biology and clinical utility.

Authors:  Sandra L Haberichter
Journal:  Blood       Date:  2015-07-27       Impact factor: 22.113

Review 6.  Acquired von Willebrand syndrome associated with left ventricular assist device.

Authors:  Angelo Nascimbene; Sriram Neelamegham; O H Frazier; Joel L Moake; Jing-Fei Dong
Journal:  Blood       Date:  2016-05-03       Impact factor: 22.113

7.  Genetic alteration of the D2 domain abolishes von Willebrand factor multimerization and trafficking into storage.

Authors:  S L Haberichter; A M Allmann; M A Jozwiak; R R Montgomery; J C Gill
Journal:  J Thromb Haemost       Date:  2009-01-17       Impact factor: 5.824

Review 8.  Recombinant von Willebrand factor: potential therapeutic use.

Authors:  B E Fischer
Journal:  J Thromb Thrombolysis       Date:  1999-10       Impact factor: 5.221

9.  Deficiency of ADAMTS-13 in pediatric patients with severe sepsis and impact on in-hospital mortality.

Authors:  Farheen Karim; Salman Naseem Adil; Bushra Afaq; Anwar Ul Haq
Journal:  BMC Pediatr       Date:  2013-03-28       Impact factor: 2.125

Review 10.  Inflammation, von Willebrand factor, and ADAMTS13.

Authors:  Junmei Chen; Dominic W Chung
Journal:  Blood       Date:  2018-06-04       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.